SCHEDULE: Vanguard Group Reports 0% Stake in Ligand Pharma

The Vanguard Group reports 0% beneficial ownership of Ligand Pharmaceuticals Inc. common stock following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 11 to Schedule 13G for Ligand Pharmaceuticals Inc.
• As of March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Ligand Pharmaceuticals Inc. common stock.
• This change follows an internal realignment on January 12, 2026, where certain subsidiaries and business divisions now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities held by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Ligand Pharmaceuticals Inc. as it primarily reflects an internal organizational change at The Vanguard Group rather than a direct positive or negative assessment of Ligand's prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like The Vanguard Group are not uncommon and typically reflect internal operational or regulatory compliance adjustments rather than a specific investment thesis change regarding the underlying company, Ligand Pharmaceuticals Inc. The disaggregation of reporting allows for more granular disclosure by individual funds or divisions.

Stakeholder Impact

• Shareholders of Ligand Pharmaceuticals Inc. may note the change in institutional ownership, though the underlying investment by Vanguard's various funds may still exist, just reported separately.

Key Dates

Keywords

Vanguard Group, Ligand Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Investment Adviser, Ownership Change